209394-27-4 Usage
Description
LADOSTIGIL, also known as TV3326, is a small molecule drug candidate with multifaceted pharmacological properties. It acts as a dual inhibitor of monoamine oxidase (MAO-A and B) and an acetylcholinesterase inhibitor, while also providing neuroprotective effects. These characteristics make LADOSTIGIL a promising therapeutic agent for various neurological and cognitive disorders.
Uses
Used in Pharmaceutical Industry:
LADOSTIGIL is used as a therapeutic agent for the treatment of Alzheimer's disease. It serves as an inhibitor of monoamine oxidase (MAO-A and B), which helps in increasing the levels of neurotransmitters such as dopamine, norepinephrine, and serotonin. Additionally, it acts as an acetylcholinesterase inhibitor, enhancing the levels of acetylcholine, a crucial neurotransmitter involved in memory and learning processes. LADOSTIGIL also exhibits neuroprotective properties, safeguarding neurons from damage and degeneration.
Furthermore, LADOSTIGIL's dual inhibitory action and neuroprotective effects make it a potential candidate for the treatment of other neurological and cognitive disorders, although this would require further research and clinical trials to confirm its efficacy and safety in those contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 209394-27-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,9,3,9 and 4 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 209394-27:
(8*2)+(7*0)+(6*9)+(5*3)+(4*9)+(3*4)+(2*2)+(1*7)=144
144 % 10 = 4
So 209394-27-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H20N2O2/c1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2/h1,6,8,11,15,17H,5,7,9-10H2,2-3H3/t15-/m1/s1
209394-27-4Relevant articles and documents
An efficient and promising method to prepare Ladostigil (TV3326) via asymmetric transfer hydrogenation catalyzed by Ru-Cs-DPEN in an HCOONa-H 2O-surfactant system
Luo, Zonghua,Qin, Fangfei,Yan, Shilei,Li, Xingshu
, p. 333 - 338 (2012)
The enantiopure multi-functional anti Alzheimer's drug, Ladostigil (TV3326), was prepared by using asymmetric transfer hydrogenation (ATH) as a key step catalyzed by Ru-Cs-DPEN in an HCOONa-H2O-surfactant system. Good chemical yields with high enantiomeric excess were obtained and the catalyst could be recycled another five times.
Process for the synthesis of enantiomeric indanylamine derivatives
-
Page/Page column 7-8, (2008/06/13)
A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presence of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)-indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)-indanols and substituted (R)-indanols.
